Kathleen D. Scott Sells 12,500 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) CFO Kathleen D. Scott sold 12,500 shares of ARS Pharmaceuticals stock in a transaction dated Wednesday, October 16th. The shares were sold at an average price of $16.00, for a total transaction of $200,000.00. Following the completion of the transaction, the chief financial officer now directly owns 4,949 shares of the company’s stock, valued at $79,184. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

ARS Pharmaceuticals Stock Down 2.4 %

NASDAQ SPRY traded down $0.39 on Thursday, hitting $16.13. The stock had a trading volume of 963,408 shares, compared to its average volume of 764,199. The company’s 50-day moving average is $13.38 and its two-hundred day moving average is $10.72. The stock has a market cap of $1.56 billion, a price-to-earnings ratio of -31.02 and a beta of 0.91. ARS Pharmaceuticals, Inc. has a one year low of $3.35 and a one year high of $16.89.

ARS Pharmaceuticals (NASDAQ:SPRY) last issued its quarterly earnings results on Tuesday, August 6th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). The firm had revenue of $0.50 million for the quarter, compared to the consensus estimate of $2.00 million. On average, sell-side analysts anticipate that ARS Pharmaceuticals, Inc. will post -0.66 earnings per share for the current year.

Institutional Trading of ARS Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. nVerses Capital LLC acquired a new stake in shares of ARS Pharmaceuticals in the 3rd quarter worth approximately $30,000. Russell Investments Group Ltd. acquired a new stake in ARS Pharmaceuticals during the first quarter valued at approximately $60,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in ARS Pharmaceuticals by 151.7% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,419 shares of the company’s stock valued at $63,000 after purchasing an additional 4,472 shares during the last quarter. Principal Financial Group Inc. acquired a new stake in ARS Pharmaceuticals during the second quarter valued at approximately $87,000. Finally, Paloma Partners Management Co acquired a new stake in ARS Pharmaceuticals during the first quarter valued at approximately $103,000. 68.16% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

SPRY has been the subject of several research reports. William Blair raised shares of ARS Pharmaceuticals to a “strong-buy” rating in a report on Friday, August 30th. Cantor Fitzgerald restated an “overweight” rating and issued a $30.00 target price on shares of ARS Pharmaceuticals in a research report on Tuesday, October 8th. Raymond James upgraded shares of ARS Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and upped their target price for the stock from $18.00 to $22.00 in a research report on Tuesday, August 13th. Finally, Leerink Partners upped their target price on shares of ARS Pharmaceuticals from $21.00 to $25.00 and gave the stock an “outperform” rating in a research report on Friday, September 20th. Four research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $24.00.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.